Cargando…
Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines
Considering the clinical significance for myocarditis and pericarditis after immunization with mRNA COVID-19 vaccines, the present pharmacovigilance study aimed to describe these events reported with mRNA COVID-19 vaccines in the Vaccine Adverse Events Reporting System (VAERS). From 1990 to July 202...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145505/ https://www.ncbi.nlm.nih.gov/pubmed/35631352 http://dx.doi.org/10.3390/ph15050525 |
_version_ | 1784716331863506944 |
---|---|
author | Rafaniello, Concetta Gaio, Mario Zinzi, Alessia Sullo, Maria Giuseppa Liguori, Valerio Ferraro, Marialuisa Petronzelli, Fiorella Felicetti, Patrizia Marchione, Pasquale Marra, Anna Rosa Rossi, Francesco De Angelis, Antonella Capuano, Annalisa |
author_facet | Rafaniello, Concetta Gaio, Mario Zinzi, Alessia Sullo, Maria Giuseppa Liguori, Valerio Ferraro, Marialuisa Petronzelli, Fiorella Felicetti, Patrizia Marchione, Pasquale Marra, Anna Rosa Rossi, Francesco De Angelis, Antonella Capuano, Annalisa |
author_sort | Rafaniello, Concetta |
collection | PubMed |
description | Considering the clinical significance for myocarditis and pericarditis after immunization with mRNA COVID-19 vaccines, the present pharmacovigilance study aimed to describe these events reported with mRNA COVID-19 vaccines in the Vaccine Adverse Events Reporting System (VAERS). From 1990 to July 2021, the mRNA vaccines were the most common suspected vaccines related to suspected cases of myocarditis and/or pericarditis (myocarditis: N = 1,165; 64.0%; pericarditis: N = 743; 55.1%), followed by smallpox vaccines (myocarditis: N = 222; 12.2%; pericarditis: N = 200; 14.8%). We assessed all suspected cases through the case definition and classification of the Brighton Collaboration Group, and only definitive, probable, and possible cases were included in the analysis. Our findings suggested that myocarditis and pericarditis mostly involve young male, especially after the second dose with a brief time to onset. Nevertheless, this risk is lower (0.38/100,000 vaccinated people; 95% CI 0.36–0.40) than the risk of developing myocarditis after SARS-CoV-2 infection (1000–4000 per 100,000 people) and the risk of developing “common” viral myocarditis (1–10 per 100,000 people/year). Comparing with the smallpox vaccine, for which is already well known the association with myocarditis and pericarditis, our analysis showed a lower probability of reporting myocarditis (ROR 0.12, 95% CI 0.10–0.14) and pericarditis (ROR 0.06, 95% CI 0.05–0.08) following immunization with mRNA COVID-19 vaccines. |
format | Online Article Text |
id | pubmed-9145505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91455052022-05-29 Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines Rafaniello, Concetta Gaio, Mario Zinzi, Alessia Sullo, Maria Giuseppa Liguori, Valerio Ferraro, Marialuisa Petronzelli, Fiorella Felicetti, Patrizia Marchione, Pasquale Marra, Anna Rosa Rossi, Francesco De Angelis, Antonella Capuano, Annalisa Pharmaceuticals (Basel) Article Considering the clinical significance for myocarditis and pericarditis after immunization with mRNA COVID-19 vaccines, the present pharmacovigilance study aimed to describe these events reported with mRNA COVID-19 vaccines in the Vaccine Adverse Events Reporting System (VAERS). From 1990 to July 2021, the mRNA vaccines were the most common suspected vaccines related to suspected cases of myocarditis and/or pericarditis (myocarditis: N = 1,165; 64.0%; pericarditis: N = 743; 55.1%), followed by smallpox vaccines (myocarditis: N = 222; 12.2%; pericarditis: N = 200; 14.8%). We assessed all suspected cases through the case definition and classification of the Brighton Collaboration Group, and only definitive, probable, and possible cases were included in the analysis. Our findings suggested that myocarditis and pericarditis mostly involve young male, especially after the second dose with a brief time to onset. Nevertheless, this risk is lower (0.38/100,000 vaccinated people; 95% CI 0.36–0.40) than the risk of developing myocarditis after SARS-CoV-2 infection (1000–4000 per 100,000 people) and the risk of developing “common” viral myocarditis (1–10 per 100,000 people/year). Comparing with the smallpox vaccine, for which is already well known the association with myocarditis and pericarditis, our analysis showed a lower probability of reporting myocarditis (ROR 0.12, 95% CI 0.10–0.14) and pericarditis (ROR 0.06, 95% CI 0.05–0.08) following immunization with mRNA COVID-19 vaccines. MDPI 2022-04-25 /pmc/articles/PMC9145505/ /pubmed/35631352 http://dx.doi.org/10.3390/ph15050525 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rafaniello, Concetta Gaio, Mario Zinzi, Alessia Sullo, Maria Giuseppa Liguori, Valerio Ferraro, Marialuisa Petronzelli, Fiorella Felicetti, Patrizia Marchione, Pasquale Marra, Anna Rosa Rossi, Francesco De Angelis, Antonella Capuano, Annalisa Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines |
title | Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines |
title_full | Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines |
title_fullStr | Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines |
title_full_unstemmed | Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines |
title_short | Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines |
title_sort | disentangling a thorny issue: myocarditis and pericarditis post covid-19 and following mrna covid-19 vaccines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145505/ https://www.ncbi.nlm.nih.gov/pubmed/35631352 http://dx.doi.org/10.3390/ph15050525 |
work_keys_str_mv | AT rafanielloconcetta disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines AT gaiomario disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines AT zinzialessia disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines AT sullomariagiuseppa disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines AT liguorivalerio disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines AT ferraromarialuisa disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines AT petronzellifiorella disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines AT felicettipatrizia disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines AT marchionepasquale disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines AT marraannarosa disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines AT rossifrancesco disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines AT deangelisantonella disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines AT capuanoannalisa disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines |